Source: MONTANA STATE UNIVERSITY submitted to
RESEARCH ON INFECTIOUS DISEASES OF ANIMALS AND THEIR MANAGEMENT IN MONTANA
Sponsoring Institution
National Institute of Food and Agriculture
Project Status
NEW
Funding Source
Reporting Frequency
Annual
Accession No.
1020062
Grant No.
(N/A)
Project No.
MONB00033
Proposal No.
(N/A)
Multistate No.
(N/A)
Program Code
(N/A)
Project Start Date
Jul 1, 2019
Project End Date
Jun 30, 2022
Grant Year
(N/A)
Project Director
Voyich, JO, M.
Recipient Organization
MONTANA STATE UNIVERSITY
(N/A)
BOZEMAN,MT 59717
Performing Department
Microbiology & Immunology
Non Technical Summary
Infectious disease causes considerable loss for livestock producers by reducing production of animal units and by reduced sales because of food safety concerns. The Microbiology and Immunology (MBI) Department is the only research unit in Montana focused on animal health, particularly on the study of infectious diseases of cattle, bison and sheep. New faculty members joining MBI are required to initiate new research projects. In addition, other faculty not on Montana Agricultural Experiment Station (MAES) funding may be hired to develop new short­ term projects. These projects are in support of the respective missions of MAES and MBI. Funding from this departmental project is to be used by these scientists to generate data to initiate new MAES projects and/or enhance existing MAES project(s) take advantage of unique opportunities and increase competitiveness for grant funding from federal agencies, such as the USDA. Support is also provided to maintain and operate departmental research facilities.Examples, of newly awarded MAES and/or initiated projects that may receive funds from this project include:New MAES projects1. Studies of alpha-herpes viruses on animal health (Taylor). Several members of viral family alpha-herpesvirinae are pathogens that have a wide and pervasive impact on animal health, agricultural practices and economic productivity. Viruses in this group include Equine Herpesvirus-1 (EHV-1), Bovine Herpesvirus-1 (BHV-1) and Suid Herpesvirus-1, also known as Aujesky's disease or Pseudorabies virus (PRV). All three viruses share the hallmarks of neurological infections, long periods of latency that complicate vaccination and control efforts, and the capacity to elicit severe disease. Despite years of research, we understand surprisingly little about the pathways that regulate neuronal transmission of viral infection. We have previously found that neuronal spread of infection involves limited numbers of infectious particles transmitted between cells. These limitations have uncharacterized effects on how these viruses interact with host immune responses and adapt to evolutionary pressures imposed by vaccination. For the state of Montana, the impact of BHV-1 and EHV-1 on cattle and horse production and transport is emergent. Infections with BHV-1 are widespread, primarily associated with infectious bovine rhinotracheitis and a strong risk factor in shipping fever disease and bovine respiratory disease complex. Severe economic losses related to BHV-1 disease are due to reduced productivity and calf abortion or developmental deformity. In unvaccinated herds, seroprevalence can reach as high as 75-80%. Vaccination efforts can reduce overt disease but it cannot fully prevent infection or eliminate spontaneous transmission. Similarly, EHV-1 can be controlled through effective vaccine and quarantine efforts, but recent cases of EHV-1 in Montana, occurring in 2011 and 2013, can be traced to transport of horses between states for competitive events. Together, BHV-1 and EHV-1 remain viruses of concern among agricultural producers both for the state of Montana as well as nationally.Our objective is to identify the molecular factors that regulate PR V infection and spread within an infected host. We aim to answer the critical questions of how exclusion affects virions and what genes are responsible. To this end, we propose experiments that will quantify PRV virion entry, assess the impact of IFN activation and signaling on SIE and replication and characterize the transcriptional responses that correlate with SIE and IFN induction. Preliminary data presented in this proposal suggests that SIE blocks viral entry. Additionally, our preliminary work points to differential effect of antiviral transcription factors needed for IFN signaling. Finally, we present preliminary evidence that differential transcriptional responses correlate with SIE induction. From our preliminary findings, we hypothesize that early transcriptional changes to viral and cellular genes, initiated by the virus, alter the cell's susceptibility to superinfection.Studies of infectious disease Spillover (P/owright). The objectives in this new project are to develop models that integrate the many processes that determine whether spillover transmission will occur, spanning spatial scales from host cells to landscapes, and to parameterize these models with existing data and data collected in the field. Our models aim to predict how the series of barriers to spillover interact to determine the risk of spillover and onward transmission. In particular, we are interested in the emergent properties of spillover. That is, we wish to investigate the patterns that arise when many non-linearly linked, and dynamic processes are combined. Our novel conceptual and quantitative framework should also reveal how past increases in spillover rates have arisen from environmental and social changes that altered the width and alignment of gaps in barriers. Our framewor k will identify the barriers most amenable to intervention and will provide the operationalized models needed to guide prediction and prevention measures against emergence of known pathogens. These models can also be used to rapidly assess the risks to human and livestock health associated with newly discovered pathogens. Moreover, these models should provide an organ izing principle for a new, integrative body of theory and transdiscipl inary spillover investigation.
Animal Health Component
100%
Research Effort Categories
Basic
75%
Applied
25%
Developmental
(N/A)
Classification

Knowledge Area (KA)Subject of Investigation (SOI)Field of Science (FOS)Percent
3153410109030%
3043999104020%
3113610107010%
3113599109020%
3113810109020%
Goals / Objectives
Infectious disease causes considerable loss for livestock producers by reducing production of animal units and by reduced sales because of food safety concerns. The Microbiology and Immunology (MBI) Department is the only research unit in Montana focused on animal health, particularly on the study of infectious diseases of cattle, bison and sheep. New faculty members joining MBI are required to initiate new research projects. In addition, other faculty not on Montana Agricultural Experiment Station (MAES) funding may be hired to develop new short­ term projects. These projects are in support of the respective missions of MAES and MBI. Funding from this departmental project is to be used by these scientists to generate data to initiate new MAES projects and/or enhance existing MAES project(s) take advantage of unique opportunities and increase competitiveness for grant funding from federal agencies, such as the USDA. Support is also provided to maintain and operate departmental research facilities.
Project Methods
MBI scientists utilize state-of-the-art molecular approaches to address basic and applied problems in infectious diseaseresearch. These research programs require laboratories, large and small animal facilities, clinics, and modern researchequipment, such as flow cytometers, DNA sequencers, and genomics analysis facilities. The study of agents, such as B. abortusrequire BSL-3 facilities approved for Select Agent work. Specific methods and procedures utilized are dependent upon programtype and necessary protocols. New or existing faculty members must develop an understanding of Montana and regional issuesand a more in-depth understanding of existing research programs, prior to developing their own MAES project proposals. Allresearch will have appropriate IBC Protocol Numbers and IACUC Protocol approvals.1. Molecular pathogenesis of West Nile Virus. West Nile virus (WNV) is an emergent neuroinvasive pathogen that causessevere illness in a wide range of vertebrates, including horses. In recently published work, we reported a restriction that limitsthe number of alphaherpes virions infecting neurons (Taylor et al., 2012). A series of experiments that aim to identify ifneuroinvasive spread of WNV is restricted in the number of virions transmitted between cells and characterize the cellularantiviral signaling activated neuronal infection of WNV will be done. By characterizing neuroinvasive spread of WNV, we willbegin to understand how neuroinvasive viruses are controlled during zoonotic infections and understand the impacts on viralpopulation biology and pathogenesis. IBC Protocol Numbers: 032-2014 (WNV), 08-2015 (recombinant Baculovirus) and IACUCProtocol: 2013-282. Genome editing through use of CRISPR technology. Cas9 is a new RNA-guide technology that permits rapid and precisemanipulation of plant and animal genomes. This new gene knockout system is revolutionizing molecular biology and the value ofthis technology is currently estimated in the billions. However, this technique has been primarily restricted to generating geneknockouts (i.e. search and delete functions). Knockouts are critical for determining the biological function of a specific gene, butthe genetic basis of many plant and animal diseases are already known and the next major advance will be to design methodsthat facilitate precise repair of defective genes (i.e. search and replace functions). Here we propose lentiviral delivery of Cas9 togenerate a genome-wide knockout library in human cells that will identify novel pathways that enhance Homology DirectedRepair (HDR) of double-stranded DNA breaks. We anticipate that many of the human genes involved in HDR will haveconserved functions in other animals and plants. Results from this screen will provide fundamental new insight into DNA repairmechanisms, and provide a foundation for designing the next generation of tools for "correcting" genetic disorders andengineering Ag related products for resistance to environmental stress, and improving food security for the rapidly expandingpoppopulation. IBC Protocol 024-2014.Mucosal immunology in pigs (NIH pilot grant peer-review). This study seeks to obtain pilot data to evaluate the currentzoonotic threat and the mechanisms of gastric pathogenesis for human Helicobacter suis (H. suis) infection. H. suis is astomach-dwelling bacterium naturally found in pigs that has been associated with gastric lesions including gastric cancer inhumans. The overall hypothesis is that H. suis is a relevant zoonotic pathogen that disrupts human gastric epithelial cellfunction by triggering inflammatory signaling. In summary, our study will elucidate inflammatory pathways induced by H. suisand will determine whether there is a need for further research into zoonotic H. suis infection. IBC protocol 042-2014.4. New vaccine development for Coxiella and Brucella (new project). Using novel virus-like particles, unique vaccine constructsare being developed for effective T cell immune responses against Coxiella burnetii and Brucella sps. Vaccine constructs willbe used to immunize animals, prior to challenge with with C. burnetii or Brucella sps. Proof of principle studies will be done inmice under BSL-3 containment. Immune reponses against each construct will also be measured in cattle as our main livestockmodel system. Here animals will be immunized with different doses of vaccine and then antibody titers and antigen-specific Tcell responses measured at different times, post vaccination.5. Funding will also be provided for new faculty who develop animal health related projects. Possible projects include diseaseecology of pneumonia in bighorn sheep and domestic sheep, and scouring diseases in cattle.

Progress 10/01/19 to 09/30/20

Outputs
Target Audience:As in our previous reporting period, we continue to focus on generating support (efficacy data) for future commercialization of TLR4 small molecule agonists and similar modulators defined in earlier studies for use in calf scours and other infectious disease settings. New publications have not been forthcoming, but a new provisonal patent application has been submitted based on results in the past year. An abstract that includes a portion of this work has been submitted to the brucellosis conference in association with USDA CRWAD this November in Chicago, and, thus, information on this project will reach investigators in the field. Changes/Problems:Change in Department Head resulted in Change of main PD listed on this project. What opportunities for training and professional development has the project provided? Nothing Reported How have the results been disseminated to communities of interest?We are focusing on the potential commercialization of small molecule TLR4 agonists and similar modulators defined in earlier studies for use in bovine scours and other infectious disease settings in cattle. A second provisonal patent application represents the main way the results were disseminated in the past year. SBIR grant applications were also submitted. An abstract that includes a portion of this work has been submitted to the brucellosis conference in association with USDA CRWAD this November in Chicago, and, thus, information on this project will reach investigators in the field. What do you plan to do during the next reporting period to accomplish the goals?We plan on continuing our in vitro mechanism of action studies and to continue testing novel approaches to increase the efficacy of the benefit seen with TLA agonists in intestinal infections in calves and, in the future, possibly respiratory infections and mastitis in cows. Based on reviewer feedback on recent grant applications, we are looking to begin testing our liposomal preparations in younger calves (0-2 week old) that will better represent the age of animals in clinical settings where these agonists might possibly be used. We intend to test the effect on naturally acquired causes of scours. Since only modest funding is provided by this Animal Health project, a major effort will continue to be securing major funding to move the potential commercialization of these agonists forward.

Impacts
What was accomplished under these goals? With the modest funding from this project, we continued testing of novel TLR4 agonists in the Salmonella enteritis model as described in previous reports. We focused exclusively on testing of a lipsome preparation of synthetic TLR4 agonists described in last year's report. Positive results were detected in vivo (reduced morbidity responses following Salmonella infection in 1-2 month old calves as measured by reduced diarrhea and improved animal demeanor), though variability was noted in some epxeriments that may relate to the "age" of the preparation. In earlier studies, we showed that the liposome preparations activated bovine gamma/delta T cells, but not monocytes, as measured by lack of upregulation of the activation marker CD69. In the past year we focused on additional in vitro assays and found that even though the preparation did not upregulate CD69 on bovine monocytes, it did increase monocyte/macrophage killing of the Salmonella bacteria in in vitro killing assays. We then tested whether this effect was unique to Salmonella and found that the liposomal-TLR4 agonist also upregulated monocyte/macrophage killing of Brucella abortus, which is being studied in a NIH R21 funded project. In vitro activation experiments continue and will be a significant focus in the coming year (see below). A second provisional patent application in partnership with Totem Bio was submitted on the use of these modulators in bovine scours and other infectious disease settings.

Publications


    Progress 07/01/19 to 09/30/19

    Outputs
    Target Audience: Nothing Reported Changes/Problems: Nothing Reported What opportunities for training and professional development has the project provided? Nothing Reported How have the results been disseminated to communities of interest? Nothing Reported What do you plan to do during the next reporting period to accomplish the goals?We plan on focusing most efforts on the development of the M. ovipenumoniae project with support specifically going towards efforts to generate novel vaccine constructs for the pathogen in sheep using the P22-VLP platform. Briefly, the next major effort will progress into running qPCR assays to determine whether inoculation of sheep with P22-VLPs reduces respiratory burden of M. ovi., as well as other pathogens. Success in these experiments will form the basis of a new grant application to USDA/NIFA.

    Impacts
    What was accomplished under these goals? Research funding was only forthcoming for the last three months of the federal fiscal year. The funds were primarily used to support a new research program on Mycoplasma ovipneumoniae in domestic sheep involving three different department investigators. Modest funding was also used to help support the research effort on gastric dendritic cells and effects of Helicobacter sps infection, including in animals (pigs). Development of a new research program in Mycosplasma ovipneumoniae. Animal Health funds were used to help establish a new research program in M. ovipneumoniae, in preparation for new competitive grant funding focused on expanding research in this area at Montana State University. Two new USDA/NIFA Seed grants were award to support this project. In preparation of this large undertaking, we have developed protocols for assessing animal health status by testing blood samples, colostrum samples and nasal swabs for the presence of relevant pathogens. Specifically, we have started screening sheep herds that could serve as a source of pregnant ewes and of screening bovine dairy herds as a source of high-quality colostrum for pathogens including M. paratuberculosis, Coxiella burnetti, Mannheimia, and M. ovi. These analyses will provide us with information on the prevalence of upper respiratory pathogens in local sheep flocks that will be used in our experiments and will help us obtain suitable colostrum sample for the lambs, both important milestones for our study. Other efforts focused on the analysis of methods to enhance innate and adaptice immune responses in the sheep lung. Studies in mice have shown that injection with empty virus capsids derived from Salmonella bacteriophage P22 (referred to herein as P22-VLPs) into the lung induces a state of immune readiness that protected mice from infection with multiple viral and bacterial pathogens. Protection induced by the P22-VLPs was not specific to any particular pathogen and lasted in mice only about 5-7 weeks. However, if pathogen-specific antigens were expressed either inside or on the surface of these P22-VLPs, they induce a long-term protection in mice against the challenge with the particular pathogen. Thus, these P22-VLPs induce transient protective responses on their own, but can also be exploited as efficacious vaccine delivery platforms for induction of long-lasting protection against a number of different pathogens. Building upon these results in mice, in this current work we plan to eventually test whether inoculation with P22-VLPs can reduce respiratory burden of M. ovipneumoniae (M. ovi) in domestic sheep. Briefly, 8 sheep were screened for pathogens as described above. All tested negative for M. paratuberculosis and C. burnetti, 4 of 8 tested positive for M. ovi, 4 of 8 tested positive for PI3 and 7 of 8 tested positive for Mannheimia. Based on the presence of these pathogens, animals were divided into two group (experimental and control), with each group containing a similar distribution of all 3 pathogens. Sheep were then inoculated with 3 doses of P22-VLPs (experimental group) or an equal volume of saline buffer (control group) on 3 consecutive days via intranasal route. The bronchoalveolar lavages, as well as nasal swabs, were collected prior to and after inoculation from each sheep to determine relative changes in burden of each of these 3 pathogens over time via qPCR. We are currently in the process of collecting final sets of samples from these sheep, and will next progress into running the qPCR assays to determine whether inoculation of sheep with P22-VLPs reduced respiratory burden of M. ovi. as well as the other two pathogens. Thus far we found that the P22-VLPs are well tolerated by the sheep. If we find that P22-VLPs can be used to reduce respiratory burden of M. ovi (and/or the other prevalent sheep pathogens), we will work toward development of these P22-VLPs as a vaccine platform against these pathogens. A grant application will be submitted in the coming year based on success in these preliminary experiments. Gastric dendritic cells and helicobacter infection. A key goal of the basic mucosal immunology research in the Bimczok laboratory is to understand interactions between dendritic cells (DCs), professional antigen-presenting cells that regulate adaptive immunity, and the mucosal epithelial cells that encounter pathogens. Their lab focuses on Helicobacter sps infection and they are currently studying infection in mice, human cells and pigs. Most recently they have focused on investigating the role of E-cadherin expression on DCs. E-cadherin is a major component of adherens junctions that mediate adhesions between individual cells, particularly in epithelial tissues. Certain subpopulations of DCs also express E-cadherin, which has been associated with an inflammatory DC phenotype. Whether DC-expressed E-cadherin enables the DCs to interact with mucosal epithelial cells has not yet been investigated and is currently under investigation. As a long term perspective, understanding how DC interact with the mucosal epithelium to access antigens has important implications for mucosal vaccine design in both humans and animal species.

    Publications